The drugmaker is paying up for a new growth engine. Is the price disciplined?
Crinetics stock nearly doubled after Vertex agreed to buy it for $10 billion. What's behind the deal, and is it worth it?
Investors favored companies benefiting from biotech deals, rising power demand from AI data centers, and cost-cutting efforts ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results